Compare Salesforce Inc (CRM) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Medtronic PLC — how do they compare? Salesforce Inc trades at $193.17 (market cap $161.73B), while Medtronic PLC trades at $90.62 (market cap $116.07B). The key difference: Salesforce Inc is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| CRM | MDT | |
|---|---|---|
Market Cap | $161.73B | $116.07B |
Sector | Technology | Health |
52-Week High | $266.23 | $105.35 |
52-Week Low | $150.12 | $73.75 |
Enterprise Value | $191.77B | $134.82B |
Dividend Yield | 0.89% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) amid recent market volatility. The stock maintains strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show bullish momentum with support at $196 and resistance at $199, though RSI levels suggest potential overbought conditions. Recent news highlights AI-driven growth opportunities but also sector-wide software stock pressures.
CRM presents a compelling investment case with analyst consensus pointing to 17% upside to the $230.83 price target. Strong cash flow generation ($13.09B operating cash flow) and AI monetization progress support growth, but risks include competitive AI landscape and macroeconomic sensitivity affecting software demand. Institutional sentiment remains positive with 75.78% buy ratings.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
